Plain-English translation of NCT06176027 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether azacytidine combined with a chemotherapy regimen called CAOLD can help treat a specific type of lymphoma (angioimmunoblastic T-cell lymphoma) that has returned after treatment or is no longer responding to existing therapies. Researchers want to see how well this medication combination works, how long people stay free from their cancer, and what side effects might occur.
Patients whose T-cell lymphoma comes back after initial treatment or doesn't respond to standard therapies have limited options and often face poor outcomes. This trial aims to find out whether this new medication combination can offer hope to people in this difficult situation.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will receive the new medication combination (azacytidine plus CAOLD) as your treatment for lymphoma. Your medical team will monitor you closely during and after treatment—checking your blood work, imaging scans, and how you're feeling—to track whether the medication is working, how long you stay free from cancer progression, and what side effects you experience. The trial will follow you over time to measure these outcomes.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China